Abstract

Objective To investigate the CpG island methylation phenotype (CIMP) in metastatic colorectal cancer (CRC) and identify the relationship between the methylation status and clinical response to Cetuximab. Methods We retrospectively reviewed the medical records of 74 patients who received Cetuximab for KRAS/NRAS wild-type metastatic CRC. Then we analyzed the relationship between CIMP and clinical response to Cetuximab, and evaluated the predictive power and value of the CIMP. Results 28.4% patients showed CIMP positive, clinical outcomes were significantly worse in the CIMP(+ ) group than in CIMP(-) group (response rate, 9.5% vs 56.6%, P=0.00; disease control rate, 23.8% vs 75.5%, P=0.00; hazard ratio for progression-free survival, HR 4.34, 95% CI 1.53~13.90, P=0.01; overall survival, HR 4.60, 95% CI 2.12~19.35, P=0.01). Conclusions CIMP is an independent poor prognosis factor in patients with KRAS wild-type metastatic colorectal cancer, and the CIMP positive patients may not benefit from Cetuximab. Key words: Metastatic colorectal cancer; CpG island methylation phenotype; Cetuximab

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.